Literature DB >> 604107

Persistence of influenza A/New Jersey/76 (Hsw1N1) antibody one year after vaccination.

G R Noble, H S Kaye, R J O'Brien, A P Kendal, D J Bregman, P F Wright, R W Amler, W R Dowdle.   

Abstract

Serum HI and neuraminidase-inhibiting (NI) antibody measurements were made at 3, 32 and 50 weeks after inactivated influenza Hsw1N1 vaccination of 438 adults in 1976. Although the highest postvaccination geometric mean HI titers were observed in persons greater than or equal to 52 years of age, the rate of antibody decline was similar in adults of all ages. In 14 children who had a seroconversion following two doses of whole virus or split virus vaccine, the geometric mean HI antibody titer was lower after the second vaccine dose than the peak titer observed in adults, and the decrease in titer was also more rapid by 4 to 7 months. One year after influenza Hsw1N1 vaccination of adults, the prevalence of homologous HI antibody greater than or equal to 40 was 71% to 97%, whereas only two of the 14 children maintained similar titers at 5 to 7 months. Neuraminidase-inhibiting antibody titer formation occurred more frequently in those without prevaccination NI antibody, but the rate of decline was also greatest in this initially seronegative group. The rate of antibody decline at one year in the population with preexisting antibody was similar to that observed for HI antibody decline in a primed population. Heterologous influenza A/Victoria/3/75 (H3N2) HI antibody formation occurred in 22% of adults aged 25 to 51 after Hsw1N1 vaccination and in 12% of those over the age of 51, but the rate of heterologous antibody decline was more rapid than that observed for homologous antibody.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 604107

Source DB:  PubMed          Journal:  Dev Biol Stand        ISSN: 0301-5149


  7 in total

1.  Antibody response and persistence in volunteers following immunization with varying dosages of a trivalent surface antigen influenza virus vaccine.

Authors:  R Jennings; T L Smith; A R Mellersh; A Clark; R C Spencer; C W Potter
Journal:  J Hyg (Lond)       Date:  1985-02

2.  Durability of antibody responses after receipt of the monovalent 2009 pandemic influenza A (H1N1) vaccine among HIV-infected and HIV-uninfected adults.

Authors:  Nancy F Crum-Cianflone; Erik Iverson; Gabriel Defang; Patrick J Blair; Lynn E Eberly; Jason Maguire; Anuradha Ganesan; Dennis Faix; Christopher Duplessis; Tahaniyat Lalani; Timothy Whitman; Carolyn Brandt; Grace Macalino; Eugene V Millar; Timothy Burgess
Journal:  Vaccine       Date:  2011-03-01       Impact factor: 3.641

3.  Systemic and local antibody responses in elderly subjects given live or inactivated influenza A virus vaccines.

Authors:  D C Powers; S D Sears; B R Murphy; B Thumar; M L Clements
Journal:  J Clin Microbiol       Date:  1989-12       Impact factor: 5.948

4.  Antibody responses after inactivated influenza vaccine in young children.

Authors:  Peter F Wright; Edith Sannella; Jian R Shi; Yuwei Zhu; Mine R Ikizler; Kathryn M Edwards
Journal:  Pediatr Infect Dis J       Date:  2008-11       Impact factor: 2.129

Review 5.  Vaccination against virus diseases.

Authors:  K R Schell
Journal:  Soz Praventivmed       Date:  1979-10

6.  Studies with inactivated equine influenza vaccine. 1. Serological responses of ponies to graded doses of vaccine.

Authors:  J M Wood; J Mumford; C Folkers; A M Scott; G C Schild
Journal:  J Hyg (Lond)       Date:  1983-06

7.  Influence of prior influenza vaccination on antibody and B-cell responses.

Authors:  Sanae Sasaki; Xiao-Song He; Tyson H Holmes; Cornelia L Dekker; George W Kemble; Ann M Arvin; Harry B Greenberg
Journal:  PLoS One       Date:  2008-08-20       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.